Cellomics announces the appointment of William Sharp as vice president, business development
William T Sharp joins Cellomics with more than twenty years of industry experience in business development, sales, marketing, and general management.
Most recently, he was vice president of business development with Gentra Systems, a privately held provider of nucleic acid purification instruments and chemistries.
Prior to Gentra, Sharp spent more than six years with Life Technologies (Invitrogen) where he had worldwide management responsibility for the company's $200 million molecular biology business as well as new business initiatives in sample preparation, bioinformatics, and amplification-related technologies.
Sharp's extensive experience also includes a number of years with Heraeus Instruments and Baxter Healthcare. "Bill is a terrific addition to Cellomics," stated Daniel Calvo, Cellomics's president and CEO.
"His experience and background will accelerate our business development initiatives in licensing and reagents.
"Bill brings tremendous commercial and operational capabilities which will help drive Cellomics into our next phase of growth". "I am pleased to join Cellomics and look forward to leading the company's efforts in making our enabling and proprietary HCS technologies broadly available to the life sciences community through a variety of licensing, collaborative development, distribution and related business transactions with others practicing "cellomics", a field the company pioneered," remarked Sharp.
"In making our HCS intellectual property widely available through licensing arrangements similar to those announced earlier this week with GE Healthcare, we believe HCS will have a significant impact in all stages of early drug discovery, systems biology, academic research and biotechnology."
